Table 3 Data of surgery and targeted therapy in recurrence/metastasis patients
Nos. | Age (years)/sex | Size | Surgical procedure | M at diagnosis | R/M site | First line therapy | Response | Time to R/M (mo) | Second line therapy | Survival status |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 31/F | 11 | Biopsy | Yes | Lung, liver, retroperitoneum | Everolimus | SD | Dead | ||
2 | 44/F | 20 | RN | No | Lung | Everolimus | PD | 32.8 | Pazopanib | Alive |
3 | 36/F | 13 | RN | No | Lung | Everolimus | SD | 30.5 | Alive | |
4 | 65/M | 17 | RN | No | Right paralumbar fossa | Everolimus | PR | 20.7 | Dead | |
5 | 29/M | 13 | RN | No | Lung, left paralumbar fossa | Everolimus | PR | 7.4 | Alive | |
6 | 62/F | 5 | RN | No | Lung, liver, lymph node, bone | Everolimus | SD | 47.7 | Dead | |
7 | 30/F | 16 | RN | No | Lung, lymph node | Everolimus | PD | 16.6 | Sorafenib | Dead |
8 | 61/M | 12.5 | Biopsy | Yes | Lung, liver, bone | Everolimus | PD | Axitinib | Dead | |
9 | 44/F | 9 | RN | No | Lung, lymph node | Everolimus | PR | 46.5 | PWR | Alive |
10 | 28/M | 15 | RN | No | Liver, lymph node | Everolimus | PD | 9.3 | Axitinib | Dead |
11 | 46/F | 20 | RN | No | Lung | Everolimus | PR | 22.3 | Alive | |
12 | 76/M | 11 | RN | No | Retroperitoneum | Everolimus | SD | 33.5 | Dead | |
13 | 46/M | 13 | RN | No | Left paralumbar fossa | Everolimus | SD | 3.5 | Alive | |
14 | 24/F | 7.2 | RN | No | Lung, lymph node | Everolimus | SD | 2.7 | Dead | |
15 | 44/M | 13.4 | RN | No | Left paralumbar fossa | Everolimus | PR | 19.5 | Alive | |
16 | 26/M | 10.1 | Biopsy | Yes | Bone, lymph node | Everolimus | PR | Alive | ||
17 | 28/F | 6 | NSS | No | Right paralumbar fossa | Everolimus | PR | 19.3 | RN | Alive |
18 | 52/F | 4.3 | NSS | No | Lung | Everolimus | SD | 17.0 | Alive | |
19 | 21/M | 5.1 | NSS | No | Right paralumbar fossa | Everolimus | SD | 21.3 | Alive | |
20 | 54/M | 7.5 | RN | No | Abdominal wall | Everolimus | PR | 28.8 | Operation | Alive |
21 | 36/F | 12 | Biopsy | Yes | Lung | Everolimus | SD | Alive |